Expert advice on managing heart and liver health together in metabolic fatty liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to significant cardiovascular risks, with cardiovascular disease being a leading cause of death.

• MASLD is increasingly recognized as a systemic metabolic disorder with implications for cardiovascular health.
• Current diagnostic tools for MASLD, such as the fibrosis-4 index and vibration-controlled transient elastography, are available but not always utilized effectively.
• Pharmacotherapies that benefit both liver and cardiovascular health are emerging, yet clinical management remains fragmented.
• The overlap between cardiology and hepatology practices often leads to under-recognition of MASLD and its associated cardiovascular risks.
• A multidisciplinary approach that includes early screening and coordinated management across specialties could improve outcomes for patients with MASLD.

Simplified